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CASE BRIEF
"LADIES AND GENTLEMEN OF THE JURY:
Molly Schwing
This case is submitted to you by asking questions about the facts,
which you must decide from the evidence you have heard at this trial...
Do not let bias, prejudice or sympathy play any part in your
deliberations."'
These are the words read to the jury members in the District
Court of Brazoria County, Texas 23rd Judicial District read before they
began deliberating the evidence set forth during a three week trial.2
The jury panel of seven men and five women heard the story of a
grieving widow named Carol Ernst.3 Carol and her husband, Robert
Ernst, lived in a smaller town of Angleton, located just south of
Houston, Texas.
4
Robert, fondly referred to as Bob, was Carol's second husband.5
Carol had divorced her first husband in the early 1980s and raised four
children as a single mother.6, Bob worked as a produce manager for
Wal-Mart.7 He led what most people would consider a healthy
lifestyle; he was an active triathlete and marathon runner.8 When Bob
began having trouble with arthritis, Carol suggested that he see his
physician and inquire about taking the prescription drug Vioxx for pain
relief.9 Bob acted on his wife's suggestion and went to his physician
seeking treatment for his arthritis. Bob's physician gave him a
prescription for Vioxx. 1
0
After only eight months of taking the arthritis painkiller, Bob
died suddenly of a heart attack at the age of fifty-nine. 11 Carol brought
suit against Merck & Co, Inc. (hereinafter "Merck"), blaming Vioxx for
'Charge of the Court, Ernst v. Merck & Co., Inc. (on file with author).2Aaron Smith, Jury: Merck negligent, CNN Money, August 22, 2005,
www.money.cnn.com/2005/08/19news/fortune500/vioxx/.
3 Marc Kaufman, Merck Found Liable in Vioxx Case, WASH. POST, Aug. 20, 2005.
4 Smith, supra note 2.
5 id.
61d
.7id.
8 Id.
9 Smith, supra note 2.
'1Id.
"Kaufman, supra note 3.
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the 2001 death of her husband. 12 In court, Carol delivered an emotional
testimony about coping with the tragic death of her husband. 1
3
On September 30, 2004, Merck voluntarily withdrew Vioxx, its
prescription medication for arthritis and acute pain, from the worldwide
pharmaceutical market. 14 At the time the drug was removed from the
market, over twenty million people had used Vioxx. 15 The withdrawal
occurred upon the emergence of the results of a three-year clinical trial
which evaluated the efficacy of Vioxx in preventing the recurrence of
colorectal polyps in patients with a history of colorectal adenomas.
16
Evidence from the clinical trial showed patients had an increased risk
of heart attack and stroke after eighteen months of taking prescription
Vioxx. 17
When Vioxx entered the pharmaceutical market in 1999, the
drug became an overnight blockbuster. Vioxx pulled in $2.5 billion in
annual sales through over 100 million prescriptions and twenty million
users. 18 This figure represented about one tenth of Merck's total
revenue. 19 The withdrawal of Vioxx from the pharmaceutical market
stunned Merck's economic position as it triggered a decrease in the
Company's stock value by approximately one-third.2 °
At the conclusion of the trial of Ernst v. Merck & Co., Inc.,
twelve jurors were asked to answer six questions. These questions
were complicated with explanations of various legal definitions and a
requirement that all affirmative answers be based on a preponderance
of the evidence standard. After only eleven hours of deliberation, the
12 Smith, supra note 2.
13 Id.
14 Id.
15 id
16 A colorectal polyp is a growth that projects from the lining of the colon or rectum.
Polyps of the colon and rectum are typically benign, but they may cause painless
rectal bleeding. Over time and when left untreated, certain types of polyps, called
adenomatous polyps, may develop into cancer. Richardf Epstein, Pharmaceutical
Innovation and Cost: An American Dilemma: Regulatory Paternalism in the Market
for Drugs: Lessons from Vioxx and Celebrex, 5 YALE J. HEALTH POL'Y & ETHICS
741, 742 (Summer, 2005).
17 The study was multi-centered, placebo-controlled, double-blind study which began
in 2000. The study monitored 2600 patients to compare results of the use of Vioxx
verses a placebo. Merck Pulls Vioxx on Cardiovascular Risk, Mealey's Product
Liability & Risk, Sept. 30, 2004.
18 Smith, supra note 2.
19 Id.
20 Id.
21 Charge of the Court, supra note 1.
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jurors returned a 10-2 verdict holding Merck responsible for Bob
Ernst's death.2
The jurors were asked the following questions and gave the
following answers:
"Was there a defect in the marketing of VIOXX at the time it left the
possession of Merck & Co., Inc. that was a producing cause of the
death of Bob Ernst?" The jurors answered yes.2 3
"Was there a design defect in VIOXX at the time it left the possession
of Merck & Co., Inc. that was a producing cause of the death of Bob
Ernst?" The jurors answered yes.
"Did the negligence, if any, of Merck & Co., Inc. proximately cause the
death of Bob Ernst?" Again, the jurors answered yes. 25
After the verdict was read, Jonathan Skidmore, attorney for
Merck, commented on this element of the verdict. He said, "We
believe that the plaintiff did not meet the standard set by Texas law to
prove Vioxx caused Mr. Ernst's death.",26 Merck claimed that Vioxx
did not cause Bob's death. Specifically, defense counsel argued "there
is no reliable scientific evidence that shows Vioxx causes cardiac
arrhythmias, which an autopsy showed was the cause of Mr. Ernst's
death, along with coronary atherosclerosis. 27  The company argued
that arrhythmia, in particular, had never been linked to Vioxx in studies
28of the drug. Thus, the result of Bob's Vioxx use was too attenuated to
be a proximate cause of his death beyond a preponderance of the
evidence.
The coroner who performed the autopsy on Bob's body testified
during the trial. The coroner admitted that Bob may have died from a
blood clot as opposed to the arrhythmia originally identified.29
Furthermore, the coroner indicated that she was not aware that Vioxx
could cause blood clots when the autopsy was performed. 30 Thus, she
did not consider the blood clots to be a possible source of Bob Ernst's
death.3'
22 Kaufman, supra note 3.
23 Charge of the Court, supra note 1.
24 Id.
25 Id.
26 Kaufman, supra note 3.
27 Id.
28 A NewsHour with Jim Lehrer Transcript, "The Vioxx Verdict," Aug. 22, 2005.
29 Kaufman, supra note 3.
30 Id.
31 id.
2005]
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After a finding of fault on behalf of Merck, the jurors continued
to answer the questions in order to reach a finding on damages. Texas
law provides that in an action where a plaintiff seeks damages, "the
trier of fact shall determine the amount of economic damages
separately from the amount of other compensatory damages. 32 Thus,
the jury instructions were carefully devised and formatted into relevant,
yet separate categories. The jurors were asked, "What sum of money,
if paid now in cash, would fairly and reasonably compensate Carol
Ernst for her damages, if any, resulting from the death of Bob Ernst?"
a. For "pecuniary loss sustained in the past," the jurors awarded
$100,000. 33
b. For "pecuniary loss that, in reasonable probability, will be sustained
in the future," the jurors awarded $350,000. 34
c. For "loss of companionship and society sustained in the past," the
jurors awarded $2 million. 35
d. For "loss of companionship and society that, in reasonable
probability, will be sustained in the future," the jurors answered $10
million.
36
e. For "mental anguish sustained in the past," the jurors answered $2
million.
37
Carol Ernst's testimony provided direct evidence of her mental
anguish. She testified about her personal use of antidepressants. This
evidence was admitted to show her difficulty in coping with the loss of
her husband.
f. For "mental anguish that, in reasonable probability, will be sustained
in the future," the jurors answered $10 million.38
When asked "do you find by clear and convincing evidence that
the harm to Bob Ernst resulted from malice attributable to Merck &
39Co., Inc?" the jurors answered yes.
Under Texas law, in order for a plaintiff to be awarded
exemplary or punitive damages, the jurors must find that the
defendant's wrongful actions were done with malice.4n This finding
must be supported by clear and convincing evidence. The clear and
32 Tex. Civ. Prac. & Rem. Code § 41.008 (2005).
33 Charge of the Court, supra note 1.
34 Id.
35 Id.
36 Id.
37 Id.
38 Charge of the Court, supra note 1.
39 Id.
40 Tex. Civ. Prac. & Rem Code § 41.008 (2005).
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convincing evidence standard for exemplary damages is a more
difficult threshold than the beyond a preponderance of the evidence
standard used to find basic civil liability.
"What sum of money, if any, should be assessed against Merck
& Co., Inc. and awarded to Carol Ernst as exemplary damages for the,9,, • • 41
death of Bob Ernst?" The jurors answered $229 million.
When determining the amount of exemplary damages, the jurors
were instructed to consider evidence relating to: the nature of the
wrong, the character of the conduct involved, the degree of culpability
of Merck, the situation and sensibilities of the parties concerned, the
extent to which such conduct offends a public sense of justice and
propriety, and the net worth of Merck.
After the verdict was announced, Mark Lanier, the attorney for
Carol Ernst, told reporters the punitive damages figure was based on
"the money Merck made and saved by putting off their product label
changes. 43  Specifically, Lanier argued that Merck had illegally
concealed information concerning the health risks associated with
Vioxx use in order to boast sales of the drug. Lainer commented on the
speculation prior to trial that Vioxx would sweep the case in reliance on
its vast array of fiscal resources. In reference to the jurors involved in
the trial, he stated that "anyone who said they are too 'small-town' or
won't understand - they are crazy." 44
Skidmore, on the other hand, argued Ernst's case did not
warrant an award of punitive damages because the injury was not a
result of malice. The attorney for Merck claimed the company "acted
responsibly: from researching Vioxx prior to approval in clinical trials
involving almost 10,000 patients, to monitoring the medicine while it
was on the market, to voluntarily withdrawing the medicine when it
did."4 5
Texas law limits the amount of recovery of exemplary
damages.46 The exemplary damages awarded may not exceed an
amount equal to the greater of two numbers. The first number
computed is two times the amount of economic damages plus an
amount equal to any non-economic damages that do not exceed
41 Charge of the Court, supra note 1.
42 Id.
43 Smith, supra note 2.
44Id.
4' Kaufman, supra note 3.
46 NewsHours, supra note 28; Tex. Civ. Prac. & Rem. Code § 41.008 (2005).
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$750,000. 47 The second number is set at $200,000.48 Because Texas
caps punitive damage awards, under the first method of computing the
limit, the verdict against Merck will be reduced to $26.1 million even
before an appeal is heard.49
The finding of this Texas jury will have a profound effect on the
thousands of other cases filed against Merck. Many financial experts
have predicted that Merck will have to settle its Vioxx cases in order to
remain a profitable company. Analysts from J.P. Morgan Chase have
estimated that Merck's liability for Vioxx could range from $8 billion
to $25 billion. 50 However, Merck has vowed that it will not settle these
cases. 
51
Commentators on the trial have stated that the jury in this case
returned a "message verdict.",52 From the outset of the case, the legal
principles seemed to weigh in favor of Merck. As previously
discussed, Carol Ernst's causation argument was much more attenuated
than thousands of other Vioxx related suit already filed. If this jury
was willing to find fault in Merck's actions in this case, it should be
even easier for plaintiffs in other cases to link injury to use of the drug.
Since the recall of Vioxx in September of 2004, about 4,200
product liability lawsuits have been filed against Merck.53  These
lawsuits constitute approximately 7,500 plaintiff groups. Estimates on
the number of patients possibly injured or killed by Vioxx use had
reached over 10,000.
54
Mr. Andrew Birchfield is a plaintiffs' attorney in a Vioxx case
scheduled to be heard in a New Orleans federal court in November
2005. 55 Mr. Birchfield is also counsel for a committee overseeing 4500
federal Vioxx lawsuits. 56 Mr. Birchfield commented on the outcome of
Ernst's case indicating that the jurors' decision will support many
others who may have been harmed by Vioxx. Specifically, Mr.
Birchfield stated that the jury heard all of the facts of the case including
information about "Merck's bad conduct, and they came to the
conclusion that Vioxx caused the death and the company needed to be
47 Tex. Civ. Prac. & Rem. Code § 41.008 (2005).
48 Id.
49 NewsHour, supra note 28.
50 Smith, supra note 2.
51 id.
52 NewsHour, supra note 28.
53 Smith, supra note 2.
54 Id.
55 Kaufman, supra note 3.
56 Id.
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punished." 57 Regardless of whether the jury in Brazoria County "let
bias, prejudice or sympathy play any part" in its deliberations, the
exemplary damages it awarded against Merck set a solemn tone for
future Vioxx litigation.
58
57 Id.
58 Charge of the Court, supra note 1.
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